secwatch.observer — SEC 8-K summary
======================================

Issuer:     SUPERNUS PHARMACEUTICALS, INC. (SUPN)
CIK:        0001356576
Form:       8-K
Filed at:   2024-05-23T23:59:59+00:00
Accession:  0001356576-24-000034
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 7.01, 9.01, 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Supernus reports positive interim Phase 2a data for SPN-817 in treatment-resistant seizures
--------------------------------------------------------------------------------

- 75% median focal seizure reduction at 3-4 mg BID in maintenance period; 86% reduction in open-label extension.
- 81% of focal-seizure subjects had ≥30% reduction; 63% had ≥50% reduction in maintenance period.
- Discontinuation rate due to AEs was 22% in titration and 2.4% in maintenance; common AEs: nausea, diarrhea, headache.
- Company plans to initiate Phase 2b study before year-end 2024; full Phase 2a topline results expected H2 2024.
- CEO states interim data provide strong evidence of clinical utility and potential differentiated treatment option.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1356576/000135657624000034/0001356576-24-000034-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1356576/000135657624000034/supn-20240523.htm
  HTML page:      https://secwatch.observer/filing/0001356576-24-000034

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer